A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Public ClinicalTrials.gov record NCT03165734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib
Study identification
- NCT ID
- NCT03165734
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 407 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 26, 2017 (Actual)
- Primary completion
- Oct 5, 2026 (Estimated)
- Completion
- Oct 13, 2028 (Estimated)
- Last update posted
- Apr 30, 2026
2017 – 2028
United States locations
- U.S. sites
- 42
- U.S. states
- 24
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center | Birmingham | Alabama | 35294 | — |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| City of Hope | Duarte | California | 91010 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA David Geffen School of Medicine | Los Angeles | California | 90095 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Centers (US Oncology/McKesson) | Boulder | Colorado | 80303 | — |
| Yale School of Medicine | New Haven | Connecticut | 06510 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| George Washington University-Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| Cleveland Clinic Florida | Weston | Florida | 33331 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center and Medical Pavilion | Westwood | Kansas | 66205 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Saint Agnes Hospital | Baltimore | Maryland | 21229 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| Regional Cancer Care Associates LLC - CCBD Division | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Hematology, PA- Columbia | Columbia | Maryland | 21044 | — |
| Michigan Medicine Hematology Clinic-Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49546 | — |
| Washington University School of Medicine-Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada- Twain Office | Las Vegas | Nevada | 89169 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Columbia University Medical Center | New York | New York | 10017 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan -Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Duke University Hospital | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44106 | — |
| The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| The Sarah Cannon Research Institute-Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Mays Cancer Center | San Antonio | Texas | 78229 | — |
| Texas Oncology- San Antonio | San Antonio | Texas | 78240 | — |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 165 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03165734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03165734 live on ClinicalTrials.gov.